Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic fibrosis drug sales.
Latest Ratings for VRTX
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | RBC Capital | Downgrades | Outperform | Sector Perform |
| Jan 2022 | BMO Capital | Upgrades | Market Perform | Outperform |
| Dec 2021 | Wells Fargo | Initiates Coverage On | Overweight |
